Eleusis Announces the Appointment of David Guyer, M.D., to Board of Directors

“We are thrilled to have David join the Eleusis team. His unparalleled experience in shepherding biotech companies through key stages of clinical and corporate development will be crucial as we take our lead ophthalmology candidate ELE-02 into the clinic,” said Shlomi Raz, Chairman and Founder of Eleusis. “We believe that topically administered 5-HT_2A agonists have the potential to treat inflammation without the serious side effects associated with corticosteroids and reach the back of the eye at clinically relevant concentrations. We are confident that David’s guidance will support the clinical development of ELE-02 and help realize its potential to transform the treatment paradigm for retinal disease.”

“This is an exciting time to join Eleusis, as recent findings have highlighted both the anti-inflammatory properties of 5-HT_2A agonists, and their potential to address unmet needs in ophthalmology,” said Dr. Guyer. “I look forward to helping the team achieve their clinical objectives as they advance their promising lead candidate, ELE-02.”

Before founding IVERIC bio (previously known as Ophthotech Corporation), Dr. Guyer was a partner at healthcare focused venture capital firm, SV Life Sciences Advisers. He also co-founded and served as Chief Executive Officer of Eyetech Pharmaceuticals from 2000 until OSI Pharmaceuticals acquired the company in 2005. Prior to his career in industry, Dr. Guyer was a Professor and Chairman of the Department of Ophthalmology at New York University School of Medicine. Dr. Guyer received a B.S. from Yale College and an M.D. from Johns Hopkins Medical School. He completed his ophthalmology residency at Wilmer Ophthalmological Institute, Johns Hopkins Hospital and a retinal fellowship at the Massachusetts Eye and Ear Infirmary at Harvard Medical School.

About Eleusis Ltd.

Eleusis is a privately-held, clinical stage life science company, established to unlock the transformative potential of psychoactive drugs, through the mitigation and management of psychoactivity. The company is developing an innovative platform of drug discovery and digital health technologies enabling the advance of therapeutics targeting urgent unmet needs across a broad spectrum of inflammatory and stress related diseases.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190923005247/en/